For mild local rashes, you can often continue treatment while monitoring symptoms
Oral treatment with -lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial
Which has the Larger Addressable Market: GLP-1 Drugs or Bariatric Surgery
Villarroya F, Cereijo R, Villarroya J, Giralt M
Food and Drug Administration (FDA) approved Zepbound injections for adults who are: Obese, defined on the Zepbound label as having a body mass index (BMI) of 30 or greater Overweight, defined on the Zepbound label as having a BMI of 27, and at least one potentially weight-related condition , such as high blood pressure, type 2 diabetes or high cholesterol Patients are typically prescribed Zepbound in addition to a reduced-calorie diet and increased physical activity
This compromised metabolic profile translates into a substantially increased risk of major adverse cardiovascular events, including myocardial infarction and ischemic stroke [32]
